You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

CLINICAL TRIALS PROFILE FOR TOBRADEX


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for TOBRADEX

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00404937 ↗ Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle Withdrawn Alcon Research Phase 3 2006-12-01 The purpose of this study is to compare the new formulation of Tobradex to the current approved formulation
OTC NCT01560962 ↗ Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis Terminated Southern California Institute for Research and Education N/A 2012-01-01 Objective: To determine the preliminary outcome of external over the counter (OTC) povidone iodine (PI) application in the management of chronic and acute blepharitis vs. currently clinically accepted medical regimen, i.e. eyelid hygiene, antibiotic drops, or antibiotic/steroid ointments. Methodology: One hundred adult patients with chronic and acute blepharitis will be enrolled and randomized into four groups. In group one, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI twice daily for 10 days and the other eye with no intervention. In group two, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive warm soaked eyelid wash. In group three, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive 1 drop of azithromycin ophthalmic solution twice daily for 10 days. In group four, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive tobradex ointment applied to the lid margin. Subjective variables assessed included itchiness, foreign body sensation and eyelid edema (grade 0-4). Objective variables assessed included lid margin redness, meibomian gland plugging and presence/absence of collarets (grade 0-4). Cultures of lid margin at the initiation and at the cessation of treatment were obtained.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for TOBRADEX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00083551 ↗ UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy Completed Celgene Corporation Phase 3 1998-08-01 This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.
NCT00083551 ↗ UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy Completed University of Arkansas Phase 3 1998-08-01 This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.
NCT00362895 ↗ A Bioequivalence Study of Tobradex AF Completed Alcon Research Phase 3 2006-04-01 The purpose of the study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.
NCT00404937 ↗ Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle Withdrawn Alcon Research Phase 3 2006-12-01 The purpose of this study is to compare the new formulation of Tobradex to the current approved formulation
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TOBRADEX

Condition Name

Condition Name for TOBRADEX
Intervention Trials
Cataract 6
Blepharitis 3
Dry Eye 1
Glaucoma, Open-Angle 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TOBRADEX
Intervention Trials
Cataract 7
Inflammation 4
Conjunctivitis 3
Blepharitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TOBRADEX

Trials by Country

Trials by Country for TOBRADEX
Location Trials
Italy 35
United States 9
Greece 2
Brazil 2
Singapore 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for TOBRADEX
Location Trials
Texas 3
Arkansas 1
New York 1
California 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TOBRADEX

Clinical Trial Phase

Clinical Trial Phase for TOBRADEX
Clinical Trial Phase Trials
Phase 4 3
Phase 3 10
Phase 1 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TOBRADEX
Clinical Trial Phase Trials
Completed 15
Unknown status 2
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TOBRADEX

Sponsor Name

Sponsor Name for TOBRADEX
Sponsor Trials
Alcon Research 6
Bausch & Lomb Incorporated 3
Veroia General Hospital 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TOBRADEX
Sponsor Trials
Industry 15
Other 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.